Brief: RhoVac Says Global COVID-19 Vaccination Roll-Out Causes Delay To RhoVac's Phase IIb Study

Chosa Oncology AB

08/03/2021 18:24

March 8 (Reuters) - RhoVac AB  RHOVAC.TE :
    * GLOBAL COVID-19 VACCINATION ROLL-OUT CAUSES DELAY TO
RHOVAC'S
PHASE IIB STUDY
    * ITS CLINICAL PHASE IIB STUDY "BRAVAC" IN PROSTATE CANCER
TO BE
FURTHER DELAYED AS COVID-19 VACCINATIONS ARE ROLLED OUT TO STUDY
POPULATION
    * PREVIOUS TARGET OF HAVING FULL RECRUITMENT RHOVAC'S PHASE
IIB
STUDY BY Q2 NO LONGER SEEMS REALISTIC
    * RHOVAC DOES NOT ANTICIPATE THAT DELAY WILL NECESSITATE
NEED FOR
FURTHER FINANCING

Source text for Eikon:  ID:nWkr2sdKxX 
Further company coverage:  RHOVAC.TE 

 ((Reuters.Briefs@thomsonreuters.com;))